Astellas Pharma Inc (OTCPK:ALPMY)
$ 9.72 -0.18 (-1.82%) Market Cap: 17.43 Bil Enterprise Value: 21.25 Bil PE Ratio: 0 PB Ratio: 1.80 GF Score: 77/100

Full Year 2021 Astellas Pharma Inc Earnings Call Transcript

Apr 27, 2021 / NTS GMT
Release Date Price: $14.72 (-3.06%)
Unidentified Company Representative

[Interpreted] Thank you very much for waiting. We'd like to begin. Thank you very much for participating in our teleconference despite your very busy schedule today. I'm delighted to serve as emcee today. I'm [Fuji] from Corporate Advocacy & Relations. Thank you very much.

Now to begin, we'd like to begin the meeting to explain our fiscal year 2020 financial results announced at 12 noon today. This is a meeting for investors and analysts. We're going to explain based on the financial results document posted on our website. So please refer to that.

Let me introduce the participants today: President and CEO, Kenji Yasukawa; CStO and CFO, Naoki Okamura; CMO, Chief Medical Officer, Bernie Zeiher; Chief Commercial Officer, Yukio Matsui; Development Project Management Head, Mike Kitagawa.

This material or presentation by representatives of the company and their answers and statements in the Q&A session includes forward-looking statements based on assumptions and beliefs in light of information currently available to management are subject to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot